F S&P 500
5,614.75 -6.75 (-0.12%) F Dow Jones
39,641.00 -54.00 (-0.14%) F Nasdaq
20,599.25 -21.50 (-0.10%) E-mini Russell 2000 Index Futur
2,040.80 -1.90 (-0.09%) Petróleo
82.83 -0.33 (-0.40%) Oro
2,392.20 -5.50 (-0.23%)
Nevro Corp. (NVRO)
Fuera de horario:
Nevro Corp.
1800 Bridge Parkway
Redwood City, CA 94065
United States
650 251 0005
https://nevro.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 1,215
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Kevin R. Thornal | President, CEO & Director | 1.37M | N/D | 1974 |
| Mr. Roderick H. MacLeod | Senior VP & CFO | 653.1k | N/D | 1967 |
| Mr. Kashif Rashid | Senior VP of Corporate Development & Chief Legal Officer | 629.62k | N/D | 1974 |
| Mr. Greg Siller | Senior VP & Chief Commercial Officer | 419.9k | N/D | 1981 |
| Mr. Christofer Christoforou | Senior VP & COO | 367.4k | N/D | 1970 |
| Ms. Angeline C. McCabe | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Ms. Shana D. Ross M.B.A. | Senior VP & Chief Human Resources Officer | N/D | N/D | 1973 |
| Dr. David Caraway M.D., Ph.D. | Senior VP & Chief Medical Officer | N/D | N/D | 1957 |
| Mr. Peter A. Socarras | VP, General Counsel & Corporate Secretary | N/D | N/D | 1981 |
Descripción
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Nevro Corp. a partir del 1 de julio de 2024 es 6. Las puntuaciones principales son Auditoría: 6; Junta: 6; Derechos del accionista: 4; Compensación: 8.
